Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$71.46 +2.3%	$70.65	$61.24 ▼ $87.68	$216.72B	0.37	5.23 million shs	6.73 million shs
GSK GSK	$38.92 +1.4%	$38.90	$31.72 ▼ $44.67	$78.62B	0.5	4.92 million shs	6.55 million shs
HLN Haleon	$10.35 -0.2%	$10.72	$8.25 ▼ $11.42	$46.61B	0.25	9.42 million shs	17.83 million shs
SN SharkNinja	$99.35 +0.4%	$90.05	$60.50 ▼ $123.00	$13.96B	1.67	1.51 million shs	1.90 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	+0.04%	-1.08%	-4.04%	-3.75%	-10.40%
GSK GSK	-0.43%	+0.31%	-6.46%	+1.48%	-0.31%
HLN Haleon	-0.24%	-1.15%	-8.80%	+1.82%	+25.42%
SN SharkNinja	+2.65%	+8.16%	+7.92%	+17.94%	+32.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Earnings & Valuation
AZN AstraZeneca	2.3005 of 5 stars	2.4	3.0	1.7	3.0	1.3
GSK GSK	2.1981 of 5 stars	1.1	4.0	2.5	2.4	2.5
HLN Haleon	2.1716 of 5 stars	2.4	3.0	2.5	1.9	1.3
SN SharkNinja	2.7419 of 5 stars	3.4	2.0	0.0	1.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN AstraZeneca	2.83	Moderate Buy	$85.00	18.95% Upside
GSK GSK	2.10	Hold	$37.38	-3.97% Downside
HLN Haleon	2.73	Moderate Buy	$12.33	19.08% Upside
SN SharkNinja	2.88	Moderate Buy	$121.50	22.29% Upside

Current Analyst Ratings Breakdown

Latest AZN, GSK, HLN, and SN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/27/2025	HLN Haleon	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/27/2025	HLN Haleon	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$13.40
5/9/2025	HLN Haleon	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$11.25
5/9/2025	SN SharkNinja	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$105.00 ➝ $120.00
5/9/2025	SN SharkNinja	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $112.00
5/9/2025	SN SharkNinja	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$85.00 ➝ $101.00
5/9/2025	SN SharkNinja	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$135.00 ➝ $120.00
5/6/2025	HLN Haleon	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/1/2025	SN SharkNinja	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$130.00 ➝ $105.00
4/28/2025	GSK GSK	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN AstraZeneca	$54.07B	4.10	$6.44 per share	11.10	$13.18 per share	5.42
GSK GSK	$40.10B	1.99	$5.66 per share	6.88	$8.07 per share	4.82
HLN Haleon	$14.35B	3.24	$0.50 per share	20.80	$4.58 per share	2.26
SN SharkNinja	$5.53B	2.53	$4.83 per share	20.57	$13.84 per share	7.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN AstraZeneca	$7.04B	$2.49	28.70	14.29	1.28	14.14%	33.14%	12.83%	7/24/2025 (Estimated)
GSK GSK	$3.29B	$1.94	20.06	8.37	1.34	9.89%	48.82%	11.15%	7/30/2025 (Estimated)
HLN Haleon	$1.84B	$0.39	26.54	21.12	2.95	12.86%	17.65%	8.58%	7/2/2025 (Estimated)
SN SharkNinja	$438.70M	$3.16	31.44	18.82	1.91	7.86%	28.89%	12.86%	8/6/2025 (Estimated)

Latest AZN, GSK, HLN, and SN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	AZN AstraZeneca	$1.11	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	SN SharkNinja	$0.73	$0.87	+$0.14	$0.83	$1.17 billion	$1.22 billion
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion
4/29/2025	Q1 2025	AZN AstraZeneca	$1.10	$1.24	+$0.14	$0.93	$13.71 billion	$13.59 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN AstraZeneca	$2.06	2.88%	N/A	82.73%	N/A
GSK GSK	$1.69	4.34%	N/A	87.11%	N/A
HLN Haleon	$0.25	2.42%	N/A	64.10%	N/A
SN SharkNinja	N/A	N/A	N/A	N/A	N/A

Latest AZN, GSK, HLN, and SN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN AstraZeneca	0.65	0.90	0.70
GSK GSK	1.21	0.87	0.58
HLN Haleon	0.53	0.98	0.78
SN SharkNinja	0.36	1.97	1.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN AstraZeneca	20.35%
GSK GSK	15.74%
HLN Haleon	6.67%
SN SharkNinja	34.77%

Insider Ownership

Company	Insider Ownership
AZN AstraZeneca	N/A
GSK GSK	10.00%
HLN Haleon	N/A
SN SharkNinja	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
GSK GSK	68,629	2.05 billion	1.84 billion	Optionable
HLN Haleon	24,561	4.49 billion	N/A	Not Optionable
SN SharkNinja	3,688	141.04 million	N/A	Not Optionable

AZN, GSK, HLN, and SN Headlines

Recent News About These Companies

Lisanti Capital Growth LLC Makes New $350,000 Investment in SharkNinja, Inc. (NYSE:SN)

June 30 at 5:21 AM | marketbeat.com

SharkNinja and Columbia Sportswear have been highlighted as Zacks Bull and Bear of the Day

June 27, 2025 | sharewise.comS

Meet a Little-Known Stock That's Outperforming Amazon and Tesla Since Going Public 2 Years Ago

June 27, 2025 | finance.yahoo.com

Will SharkNinja (SN) be Able to Deliver Durable Above-Industry Growth?

June 27, 2025 | msn.com

SharkNinja Named to TIME’s List of the TIME100 Most Influential Companies of 2025

June 26, 2025 | finance.yahoo.com

Comparing SharkNinja (SN) and Its Rivals

June 26, 2025 | americanbankingnews.com

Lecap Asset Management Ltd. Makes New Investment in SharkNinja, Inc. (NYSE:SN)

June 25, 2025 | marketbeat.com

SharkNinja, Apple Original Films Partner for “F1 The Movie,” Launches Limited-Edition Product Line

June 25, 2025 | msn.com

SharkNinja: Stock Is Looking Intriguing Again (Rating Upgrade)

June 23, 2025 | seekingalpha.com

SG Americas Securities LLC Increases Stock Position in SharkNinja, Inc. (NYSE:SN)

June 23, 2025 | marketbeat.com

SharkNinja, Inc. (NYSE:SN) Receives $121.50 Average Price Target from Analysts

June 22, 2025 | americanbankingnews.com

GAM Holding AG Increases Stake in SharkNinja, Inc. (NYSE:SN)

June 21, 2025 | marketbeat.com

SharkNinja, Inc. (SN) Gains As Market Dips: What You Should Know

June 20, 2025 | msn.com

SharkNinja, Inc. (NYSE:SN) Receives Consensus Rating of "Moderate Buy" from Analysts

June 19, 2025 | marketbeat.com

SharkNinja (NYSE:SN) Stock Price Up 4.9% - Still a Buy?

June 18, 2025 | marketbeat.com

Analyst IMS Investment Management Services Ltd. Takes $651,000 Position in SharkNinja, Inc. (NYSE:SN)

June 18, 2025 | marketbeat.com

Looking for Red-Hot Growth Stocks? These 4 US Companies Could be Right for Your Portfolio

June 16, 2025 | sg.finance.yahoo.com

SharkNinja releases a product collection inspired by the upcoming F1 movie

June 16, 2025 | msn.com

Handelsbanken Fonder AB Increases Stake in SharkNinja, Inc. (NYSE:SN)

June 15, 2025 | marketbeat.com

SharkNinja, Inc. (NYSE:SN) Shares Bought by Azzad Asset Management Inc. ADV

June 14, 2025 | marketbeat.com

GAMMA Investing LLC Has $2.46 Million Stock Holdings in SharkNinja, Inc. (NYSE:SN)

June 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZN, GSK, HLN, and SN Company Descriptions

AstraZeneca NASDAQ:AZN

$71.46 +1.58 (+2.26%)

Closing price 04:00 PM Eastern

Extended Trading

$71.50 +0.04 (+0.06%)

As of 07:57 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

GSK NYSE:GSK

$38.92 +0.52 (+1.35%)

Closing price 03:59 PM Eastern

Extended Trading

$38.88 -0.05 (-0.12%)

As of 07:38 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Haleon NYSE:HLN

$10.35 -0.02 (-0.19%)

Closing price 03:59 PM Eastern

Extended Trading

$10.42 +0.08 (+0.72%)

As of 07:31 PM Eastern

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

SharkNinja NYSE:SN

$99.35 +0.36 (+0.36%)

Closing price 03:59 PM Eastern

Extended Trading

$98.10 -1.24 (-1.25%)

As of 07:55 PM Eastern

SharkNinja, Inc., a product design and technology company, engages in the provision of various solutions for consumers worldwide. It offers cleaning appliances, including corded and cordless vacuums, including handheld and robotic vacuums, as well as other floorcare products comprising steam mops, wet/dry cleaning floor products, and carpet extraction; cooking and beverage appliances, such as air fryers, multi-cookers, outdoor and countertop grills and ovens, coffee systems, carbonation, cookware, cutlery, kettles, toasters and bakeware; food preparation appliances comprising blenders, food processors, ice cream makers, and juicers; and beauty appliances, such as hair dryers and stylers, as well as home environment products comprising air purifiers and humidifiers. The company sells its products through traditional brick-and-mortar retail channels and e-commerce channels, distributors, and direct-to-consumer channels under the Shark and Ninja brands. SharkNinja, Inc. was incorporated in 2017 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time